Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02972840 · ClinicalTrials.gov registry record · Phase 3

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

A Phase 3 study of Lymphoma, Mantle-Cell, sponsored by Acerta Pharma.

Active
Registry status
Phase 3
Development phase
635
Enrollment target
20
Study locations

NCT02972840 is a Phase 3 study of Lymphoma, Mantle-Cell that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 635 participants, above the 146-participant average among 7 other Lymphoma, Mantle-Cell trials with a reported enrollment target (335% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02972840, a Phase 3 study of Lymphoma, Mantle-Cell, is active but no longer recruiting, sponsored by Acerta Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
635 participants
Enrollment target
20
Study locations

Study Summary

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

Conditions Studied

Lymphoma, Mantle-Cell

Interventions

  • DRUG Placebo
  • DRUG Rituximab
  • DRUG Acalabrutinib
  • DRUG Bendamustine

Study Locations (20)

California

  • Research Site - Downey
  • Research Site - Santa Monica

Florida

  • Research Site - Tallahassee
  • Research Site - West Palm Beach

Missouri

  • Research Site - Kansas City
  • Research Site - St Louis

New Jersey

  • Research Site - Hackensack
  • Research Site - Morristown

New York

  • Research Site - Hawthorne
  • Research Site - Lake Success

Arizona

  • Research Site - Tucson

Connecticut

  • Research Site - New Haven

District of Columbia

  • Research Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 635 participants
Start Date 2017-04-05
Est. Completion 2027-02-15
Phase Phase 3

Sponsor

Acerta Pharma

38 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02972840

The ClinicalTrials.gov registry entry for NCT02972840 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 635 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 7 other Lymphoma, Mantle-Cell trials with a reported enrollment target (335% higher). The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma, Mantle-Cell appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02972840 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Missouri.

Frequently Asked Questions

What is clinical trial NCT02972840 about?

NCT02972840 is a clinical study titled "A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL". This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

What is the current status of trial NCT02972840?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 635 participants. The study started on 2017-04-05. Estimated completion is 2027-02-15.

What conditions does trial NCT02972840 study?

This clinical trial studies the following conditions: Lymphoma, Mantle-Cell.

What interventions are being tested in trial NCT02972840?

The interventions under investigation include: Placebo (DRUG), Rituximab (DRUG), Acalabrutinib (DRUG), Bendamustine (DRUG).

Who is sponsoring clinical trial NCT02972840?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02972840 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, Mantle-Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, Mantle-Cell

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.